Key facts
- CAPS Medical’s last known valuation is $16.9M (Apr 2022).
- It has raised $11.1M; the latest was Later Stage VC ($2.0M) in Mar 2025.
- Notable investors include Innovation Authority, ARC Innovation Center, Chasing Value Asset Management, Israel Investment Fund Group, MEDX Xelerator — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for CAPS Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for CAPS Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CAPS Medical
Developer of a plasma technology-enabled medical device intended to treat cancer. The company focuses on the commercialization of a minimally invasive and selective cancer treatment using non-thermal atmospheric plasma that is applicable for a wide range of solid tumors, enabling the healthcare industry with a treatment for cancer without damaging surrounding healthy tissue.
- Sector
- Healthcare
- HQ
- Netanya, Israel
- Founded
- 2018
- Employees
- 13
- Website
- capsmedical.com/
- Ownership
- Privately Held (backing)
CAPS Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CAPS Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CAPS Medical in its N-PORT filings yet. We sweep new filings monthly.